Supercharged immune cells take on Hard-to-Treat cancers
NCT ID NCT07474168
First seen Mar 20, 2026 · Last updated Apr 30, 2026 · Updated 8 times
Summary
This early-phase study tests a new cell therapy (NW-301VT) for people with advanced solid tumors that have a specific KRAS mutation and a particular immune type (HLA-A*11:01). The treatment involves taking a patient's own T cells, genetically engineering them to recognize and attack cancer cells while resisting tumor-suppressing signals, and infusing them back. The main goal is to check safety and find the right dose, with early signs of tumor shrinkage also being measured.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Zhejiang University school of Medicine
Hangzhou, Zhejiang, China
Conditions
Explore the condition pages connected to this study.